Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

244
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
244
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

102
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
102
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

147
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
147
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

172
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
172
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

486
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
486
Tumor Progression02:07

Tumor Progression

6.9K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systematic Review: Prognostic Molecular Biomarkers in Wilms Tumors.

JCO precision oncology·2026
Same author

SMARCB1 missense mutants disrupt SWI/SNF complex stability and remodeling activity.

Nature communications·2026
Same author

Checkpoint Inhibitors and Beyond: A Systematic Review of Immunotherapy in Cutaneous Malignancies.

Cureus·2026
Same author

Relapsed rhabdoid tumours and other non-nephroblastoma childhood and adolescent kidney tumours: perspectives from the HARMONICA collaboration.

Nature reviews. Urology·2026
Same author

In-Person and Virtual Adaptation of an Interprofessional Palliative Care Communications Skills Training Course for Pediatric Oncology Clinicians.

Advances in cancer education and quality improvement·2025
Same author

Fundamentals of Pediatric Cancer: How Pediatric Pathology and Infrastructure of Clinical Trials Impact Contemporary Interventional Oncology in Children.

Seminars in interventional radiology·2025

Related Experiment Video

Updated: Nov 17, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.9K

Progress Update in Pediatric Renal Tumors.

Juhi Jain1,2,3, Kathryn S Sutton1,2,4, Andrew L Hong5,6,7,8

  • 1Aflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.

Current Oncology Reports
|February 16, 2021
PubMed
Summary
This summary is machine-generated.

Recent clinical trials have improved outcomes for pediatric renal tumors, but rarer cancers still need new treatments. Future research will balance efficacy and toxicity for better pediatric cancer care.

Keywords:
1q GainAREN0321AREN0532AREN0533AREN0534Clear-cell sarcoma of the kidneyLOH 1p/16qMalignant rhabdoid tumorMesoblastic nephromasPediatric renal tumorsWilms tumor

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.0K
Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression
06:29

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression

Published on: January 31, 2025

981

Related Experiment Videos

Last Updated: Nov 17, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.9K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.0K
Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression
06:29

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression

Published on: January 31, 2025

981

Area of Science:

  • Pediatric oncology
  • Renal tumor research
  • Cancer clinical trials

Background:

  • Pediatric renal tumors represent 7% of childhood cancer diagnoses.
  • Significant advancements have been made in treating pediatric tumors through cooperative group trials.
  • Standardized treatments for rare pediatric renal cancers, like bilateral Wilms tumor, have improved patient outcomes.

Purpose of the Study:

  • To review outcomes from recent clinical trials for pediatric renal tumors.
  • To discuss the current standard of care for these malignancies.
  • To explore targeted and immune therapies for high-risk or refractory pediatric renal cancers.

Main Methods:

  • Review of results from recently completed clinical trials.
  • Analysis of treatment strategies for pediatric renal malignancies.
  • Exploration of novel therapeutic approaches including targeted and immune therapies.

Main Results:

  • Improvements in event-free and overall survival observed in recent clinical trials for many pediatric renal tumors.
  • Enhanced outcomes noted for rare pediatric cancers treated with standardized protocols.
  • Persistent poor outcomes in specific subsets of rarer pediatric renal cancers highlight the need for new strategies.

Conclusions:

  • Cooperative group trials have significantly improved the care and survival rates for children with various pediatric renal tumors.
  • While progress has been made, novel therapeutic strategies are essential for subsets of rarer pediatric renal cancers with poor prognoses.
  • Future clinical trials will focus on optimizing treatment efficacy and minimizing toxicity for improved pediatric cancer management.